Al-Bishri J, Attar Sm, Bassuni Nawal, Al-Nofaiey Yasser, Qutbuddeen Hamed, Al-Harthi Salma, Subahi Sarah
Department of internal Medicine, Taif University, Taif, PO Box 11153, Saudi Arabia.
Clin Med Insights Arthritis Musculoskelet Disord. 2013 Apr 4;6:11-8. doi: 10.4137/CMAMD.S11481. Print 2013.
Comorbid conditions play a pivotal role in rheumatoid arthritis management and outcomes. We estimated the percentage of comorbid illness among rheumatoid arthritis patients and explored the relationship between this comorbidity and different prescriptions. A cross-sectional study of patients with rheumatoid arthritis in three centers in Saudi Arabia was carried out. Comorbidity and antirheumatoid medication regimens prescribed were recorded on a specially designed Performa. The association between comorbidity and different drugs was analyzed. A total of 340 patients were included. The most comorbidities were hypertension 122 (35.9%), diabetes 105 (30.9%), osteoporosis 88 (25.8%), and dyslipidemia in 66 (19.4). The most common drug prescribed was prednisolone in 275 (80.8%) patients followed by methotrexate in 253 (74.4%) and biological therapy in 142 (41.5%) patients. Glucocorticoids were prescribed considerably more frequently in hypertensive and diabetic patients as well as in patients with osteoporosis and dyslipidemia. Most patients with rheumatoid arthritis suffered from comorbid diseases.
合并症在类风湿关节炎的管理及预后中起着关键作用。我们估算了类风湿关节炎患者中合并症的比例，并探究了这种合并症与不同处方之间的关系。在沙特阿拉伯的三个中心开展了一项针对类风湿关节炎患者的横断面研究。在一份专门设计的表格上记录合并症情况及所开具的抗类风湿药物治疗方案。分析了合并症与不同药物之间的关联。共纳入340例患者。最常见的合并症为高血压122例（35.9%）、糖尿病105例（30.9%）、骨质疏松症88例（25.8%）以及血脂异常66例（19.4%）。最常开具的药物是泼尼松龙，275例（80.8%）患者使用，其次是甲氨蝶呤，253例（74.4%）患者使用，生物治疗142例（41.5%）患者使用。高血压、糖尿病、骨质疏松症及血脂异常患者使用糖皮质激素的频率明显更高。大多数类风湿关节炎患者患有合并症。
